4.67
0.30 (6.86%)
| Previous Close | 4.37 |
| Open | 4.38 |
| Volume | 230,683 |
| Avg. Volume (3M) | 208,119 |
| Market Cap | 216,326,800 |
| Price / Sales | 5.51 |
| Price / Book | 13.14 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -15.10% |
| Operating Margin (TTM) | -12.92% |
| Diluted EPS (TTM) | -0.120 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 22.83% |
| Current Ratio (MRQ) | 2.44 |
| Levered Free Cash Flow (TTM) | 1.05 M |
| Return on Assets (TTM) | -13.09% |
| Return on Equity (TTM) | -29.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | KORU Medical Systems, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 7.65% |
| % Held by Institutions | 51.77% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Lake Street, 71.31%) | Buy |
| Median | 7.00 (49.89%) | |
| Low | 6.00 (Canaccord Genuity, 28.48%) | Buy |
| Average | 7.00 (49.89%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Lake Street | 22 Dec 2025 | 8.00 (71.31%) | Buy | 6.07 |
| Canaccord Genuity | 17 Dec 2025 | 6.00 (28.48%) | Buy | 5.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System |
| 12 Jan 2026 | Announcement | KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow |
| 05 Jan 2026 | Announcement | KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Dec 2025 | Announcement | KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic |
| 16 Dec 2025 | Announcement | KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |